Polyalanine tract disorders and neurocognitive phenotypes

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 185-203

  Shoubridge, Cheryl ^a,b   Gecz, Jozef ^a,b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GUANINE; METABOTROPIC RECEPTOR; POLYGLUTAMINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; DNA; POLYALANINE; POLYAMINOACID; UNCLASSIFIED DRUG;

ARTICLE; ARX GENE; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; FAMILIAL DISEASE; FOXL2 GENE; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HAPLOINSUFFICIENCY; HOXA13 GENE; HOXD13 GENE; HUMAN; INTELLECTUAL IMPAIRMENT; LATER ONSET OCULOPHARYNGEAL MYOTONIC DYSTROPHY; NONHUMAN; PABPN1 GENE; PATHOGENESIS; PHENOTYPE; PHOX2B GENE; POLYGLUTAMINE TRACT DISORDER; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; RUNX2 GENE; SIGNAL TRANSDUCTION; SOX3 GENE; SYNPOLYDACTYLY; X CHROMOSOME; X CHROMOSOME LINKED DISORDER; ZIC2 GENE; AUTOSOMAL DOMINANT DISORDER; CONGENITAL DISORDER; DNA MUTATIONAL ANALYSIS; HOMOLOGOUS RECOMBINATION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOLECULAR PATHOLOGY; PENETRANCE; POLYALANINE TRACT EXPANSION DISORDER;

EID: 84934435674     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_12     Document Type: Article

References (85)

1. Albrecht A, Mundlos S. The other trinucleotide repeat: polyalanine expansion disorders. Curr Opin Genet Dev 2005; 15(3):285-293.
2. Lavoie H, Debeane F, Trinh QD et al. Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Hum Mol Genet 2003; 12(22):2967-2979.
3. La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11(4):247-258.
4. McMurray CT. Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet 11(11):786-799.
5. Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 2009; 110(6):1737-1765.
6. Li LB, Bonini NM. Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci 33(6):292-298.
7. Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? What is toxicity? Where are we going? J Mol Cell Biol 2(4):180-191.
8. Calado A, Tome FM, Brais B et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000; 9(15): 2321-2328.
9. Abu-Baker A, Messaed C, Laganiere J et al. Involvement ofthe ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003; 12(20):2609-2623.
10. Goodman FR, Bacchelli C, Brady AF et al. Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am J Hum Genet 2000; 67(1):197-202.
11. Utsch B, Becker K, Brock D et al. A novel stable polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital syndrome: proper function of poly(A)-harbouring transcription factors depends on a critical repeat length? Hum Genet 2002; 110(5):488-494.
12. Debeer P, Bacchelli C, Scambler PJ et al. Severe digital abnormalities in a patient heterozygous for both a novel missense mutation in HOXD13 and a polyalanine tract expansion in HOXA13. J Med Genet 2002; 39(11):852-856.
13. Innis JW, Mortlock D, Chen Z et al. Polyalanine expansion in HOXA13: three new affected families and the molecular consequences in a mouse model. Hum Mol Genet 2004; 13(22):2841-2851.
14. Utsch B, McCabe CD, Galbraith K et al. Molecular characterization of HOXA13 polyalanine expansion proteins in hand-foot-genital syndrome. Am J Med Genet A 2007; 143A(24):3161-3168.
15. Roessler E, Lacbawan F, Dubourg C et al. The full spectrum of holoprosencephaly-associated mutations within the ZIC2 gene in humans predicts loss-of-function as the predominant disease mechanism. Hum Mutat 2009; 30(4):E541-E554.
16. Brown L, Paraso M, Arkell R et al. In vitro analysis of partial loss-of-function ZIC2 mutations in holoprosencephaly: alanine tract expansion modulates DNA binding and transactivation. Hum Mol Genet 2005; 14(3):411-420.
17. Danckwardt S, Hentze MW, Kulozik AE. 3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J 2008; 27(3):482-498.
18. Brais B, Bouchard JP, Xie YG et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18(2):164-167.
19. Robinson DO, Wills AJ, Hammans SR et al. Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation. J Med Genet 2006; 43(5):e23.
20. Mundlos S, Otto F, Mundlos C et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89(5):773-779.
21. Cunningham ML, Seto ML, Hing AV et al. Cleidocranial dysplasia with severe parietal bone dysplasia: C-terminal RUNX2 mutations. Birth Defects Res A Clin Mol Teratol 2006; 76(2):78-85.
22. Beysen D, Moumne L, Veitia R et al. Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation. Hum Mol Genet 2008; 17(13):2030-2038.
23. Crisponi L, Deiana M, Loi A et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27(2):159-166.
24. De Baere E, Dixon MJ, Small KW et al. Spectrum of FOXL2 gene mutations in blepharophimosis- ptosis-epicanthus inversus (BPES) families demonstrates a genotype - phenotype correlation. Hum Mol Genet 2001; 10(15):1591-1600.
25. Nallathambi J, Moumne L, De Baere E et al. A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. Hum Genet 2007; 121(1):107-112.
26. Goodman FR, Mundlos S, Muragaki Y et al. Synpolydactyly phenotypes correlate with size of expansions in HOXD13 polyalanine tract. Proc Natl Acad Sci USA 1997; 94(14):7458-7463.
27. Matera I, Bachetti T, Puppo F et al. PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset Central Hypoventilation syndrome. J Med Genet 2004; 41(5):373-380.
28. Akarsu AN, Stoilov I, Yilmaz E et al. Genomic structure of HOXD13 gene: a nine polyalanine duplication causes synpolydactyly in two unrelated families. Hum Mol Genet 1996; 5(7):945-952.
29. Muragaki Y, Mundlos S, Upton J et al. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 1996; 272(5261):548-551.
30. Kjaer KW, Hedeboe J, Bugge M et al. HOXD13 polyalanine tract expansion in classical synpolydactyly type Vordingborg. Am J Med Genet 2002; 110(2):116-121.
31. Johnson D, Kan SH, Oldridge M et al. Missense mutations in the homeodomain of HOXD13 are associated with brachydactyly types D and E. Am J Hum Genet 2003; 72(4):984-997.
32. Kjaer KW, Hansen L, Eiberg H et al. A 72-year-old Danish puzzle resolved - comparative analysis of phenotypes in families with different-sized HOXD13 polyalanine expansions. Am J Med Genet A 2005; 138(4):328-339.
33. Amiel J, Laudier B, Attie-Bitach T et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet 2003; 33(4):459-461.
34. Sasaki A, Kanai M, Kijima K et al. Molecular analysis of congenital central hypoventilation syndrome. Hum Genet 2003; 114(1):22-26.
35. Weese-Mayer DE, Berry-Kravis EM, Zhou L et al. Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinentto early autonomic nervous system embryologic development and identification of mutations in PHOX2b. Am J Med Genet A 2003; 123A(3):267-278.
36. Dobyns WB. The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr Suppl 2006; 95(451):11-15.
37. Turner G, Partington M, Kerr B et al. Variable expression of mental retardation, autism, seizures and dystonic hand movements in two families with an identical ARX gene mutation. Am J Med Genet 2002; 112(4):405-411.
38. Partington MW, Turner G, Boyle J et al. Three new families with X-linked mental retardation caused by the 428-451dup(24bp) mutation in ARX. Clin Genet 2004; 66(1):39-45.
39. Gecz J, Cloosterman D, Partington M. ARX: a gene for all seasons. Curr Opin Genet Dev 2006; 16(3): 308-316.
40. Shoubridge C, Fullston T, Gecz J. ARX spectrum disorders: making inroads into the molecular pathology. Hum Mutat 31(8):889-900.
41. Stromme P, Mangelsdorf ME, Shaw MA et al. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 2002; 30(4):441-445.
42. Reish O, Fullston T, Regev M et al. A novel de novo 27 bp duplication of the ARX gene, resulting from postzygotic mosaicism and leading to three severely affected males in two generations. Am J Med Genet A 2009; 149A(8):1655-1660.
43. Demos MK, Fullston T, Partington MW et al. Clinical study of two brothers with a novel 33 bp duplication in the ARX gene. Am J Med Genet A 2009; 149A(7):1482-1486.
44. Kitamura K, Yanazawa M, Sugiyama N et al. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 2002; 32(3):359-369.
45. Kato M, Das S, Petras K et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat 2004; 23(2):147-159.
46. Nasrallah IM, Minarcik JC, Golden JA. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol 2004; 167(3):411-416.
47. Shoubridge C, Cloosterman D, Parkinson-Lawerence E et al. Molecular pathology of expanded polyalanine tract mutations in the Aristaless-related homeobox gene. Genomics 2007; 90(1):59-71.
48. McKenzie O, Ponte I, Mangelsdorf M et al. Aristaless-related homeobox gene, the gene responsible for West syndrome and related disorders, is a Groucho/transducin-like enhancer of split dependent transcriptional repressor. Neuroscience 2007; 146(1):236-247.
49. Laumonnier F, Ronce N, Hamel BC et al. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet 2002; 71(6):1450-1455.
50. Woods KS, Cundall M, Turton J et al. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005; 76(5):833-849.
51. Wong J, Farlie P, Holbert S et al. Polyalanine expansion mutations in the X-linked hypopituitarism gene SOX3 result in aggresome formation and impaired transactivation. Front Biosci 2007; 12:2085-2095.
52. Bienvenu T, Poirier K, Friocourt G et al. ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. Hum Mol Genet 2002; 11(8):981-991.
53. Trochet D, Hong SJ, Lim JK et al. Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum Mol Genet 2005; 14(23):3697-3708.
54. Warren ST. Polyalanine expansion in synpolydactyly might result from unequal crossing-over of HOXD13. Science 1997; 275(5298):408-409.
55. Brown LY, Odent S, David V et al. Holoprosencephaly due to mutations in ZIC2: alanine tract expansion mutations may be caused by parental somatic recombination. Hum Mol Genet 2001; 10(8):791-796.
56. Scheffer IE, Wallace RH, Phillips FL et al. X-linked myoclonic epilepsy with spasticity and intellectual disability: mutation in the homeobox gene ARX. Neurology 2002; 59(3):348-356.
57. Eichler EE, Holden JJ, Popovich BW et al. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet 1994; 8(1):88-94.
58. Kato M, Saitoh S, Kamei A et al. A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet 2007; 81(2):361-366.
59. De Baere E, Beysen D, Oley C et al. FOXL2 and BPES: mutational hotspots, phenotypic variability and revision of the genotype-phenotype correlation. Am J Hum Genet 2003; 72(2):478-487.
60. Robinson DO, Hammans SR, Read SP et al. Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet 2005; 116(4):267-271.
61. Trochet D, de Pontual L, Keren B et al. Polyalanine expansions might not result from unequal crossing-over. Hum Mutat 2007; 28(10):1043-1044.
62. Lee JA, Carvalho CM, Lupski Jr. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell 2007; 131(7):1235-1247.
63. Gu W, Zhang F, Lupski Jr. Mechanisms for human genomic rearrangements. Pathogenetics 2008; 1(1):4.
64. Cocquempot O, Brault V, Babinet C et al. Fork stalling and template switching as a mechanism for polyalanine tract expansion affecting the DYC mutant of HOXD13, a new murine model of synpolydactyly. Genetics 2009; 183(1):23-30.
65. Johnson KR, Sweet HO, Donahue LR et al. A new spontaneous mouse mutation of Hoxd13 with a polyalanine expansion and phenotype similar to human synpolydactyly. Hum Mol Genet 1998; 7(6):1033-1038.
66. Bruneau S, Johnson KR, Yamamoto M et al. The mouse Hoxd13(spdh) mutation, a polyalanine expansion similar to human type II synpolydactyly (SPD), disrupts the function but not the expression of other Hoxd genes. Dev Biol 2001; 237(2):345-353.
67. Albrecht AN, Schwabe GC, Stricker S et al. The synpolydactyly homolog (spdh) mutation in the mouse - a defect in patterning and growth of limb cartilage elements. Mech Dev 2002; 112(1-2):53-67.
68. Messaed C, Rouleau GA. Molecular mechanisms underlying polyalanine diseases. Neurobiol Dis 2009; 34(3):397-405.
69. Bachetti T, Matera I, Borghini S et al. Distinct pathogenetic mechanisms for PHOX2B associated polyalanine expansions and frameshift mutations in congenital central hypoventilation syndrome. Hum Mol Genet 2005; 14(13):1815-1824.
70. Zakany J, Duboule D. Hox genes in digit development and evolution. Cell Tissue Res 1999; 296(1):19-25.
71. Caburet S, Demarez A, Moumne L et al. A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J Med Genet 2004; 41(12):932-936.
72. Albrecht AN, Kornak U, Boddrich A et al. A molecular pathogenesis for transcription factor associated poly-alanine tract expansions. Hum Mol Genet 2004; 13(20):2351-2359.
73. Moumne L, Dipietromaria A, Batista F et al. Differential aggregation and functional impairment induced by polyalanine expansions in FOXL2, a transcription factor involved in cranio-facial and ovarian development. Hum Mol Genet 2008; 17(7):1010-1019.
74. Dipietromaria A, Benayoun BA, Todeschini AL et al. Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. Hum Mol Genet 2009; 18(17):3324-3333.
75. Bachetti T, Bocca P, Borghini S et al. Geldanamycin promotes nuclear localisation and clearance of PHOX2B misfolded proteins containing polyalanine expansions. Int J Biochem Cell Biol 2007; 39(2):327-339.
76. Wang Q, Mosser DD, Bag J. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 2005; 14(23):3673-3684.
77. Tome FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 1980; 49(1):85-87.
78. Klein AF, Ebihara M, Alexander C et al. PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. Exp Cell Res 2008; 314(8):1652-1666.
79. Tavanez JP, Bengoechea R, Berciano MT et al. Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE 2009; 4(7):e6418.
80. Price MG, Yoo JW, Burgess DL et al. A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures and adult cognitive and behavioral impairment. J Neurosci 2009; 29(27):8752-8763.
81. Kitamura K, Itou Y, Yanazawa M et al. Three human ARX mutations cause the lissencephaly-like and mental retardation with epilepsy-like pleiotropic phenotypes in mice. Hum Mol Genet 2009; 18(19):3708-3724.
82. Kuss P, Villavicencio-Lorini P, Witte F et al. Mutant Hoxd13 induces extra digits in a mouse model of synpolydactyly directly and by decreasing retinoic acid synthesis. J Clin Invest 2009; 119(1):146-156.
83. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27(7):370-377.
84. Dolen G, Osterweil E, Rao BS et al. Correction of fragile X syndrome in mice. Neuron 2007; 56(6):955-962.
85. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7(10):854-868.